Somerset Medical Center, established in 1899, has long served as a cornerstone of community health, providing medical services and health education to the greater Somerset County area. This legacy of general health information dissemination reflects a broad commitment to public well-being, encompassing a wide range of clinical topics and preventive care guidance. Within this tradition of accessible health knowledge, the evolution of medical understanding has increasingly required specialized attention to the effects of pharmaceutical interventions. As the center’s educational role expanded, it became necessary to address not only general wellness but also specific adverse outcomes associated with long-term medication use. One such area of focus involves the relationship between bisphosphonate therapy, commonly prescribed for bone density disorders, and the development of osteonecrosis of the jaw. This condition, characterized by exposed necrotic bone in the maxillofacial region, has emerged as a significant clinical consideration. The pivot from broad health education to this specific concern mirrors a shift in public health priorities: from general awareness to targeted risk communication. In this context, the occupational exposure dimension becomes relevant, as healthcare professionals and patients alike must navigate the eligibility criteria and medical context surrounding Fosamax use and its potential jaw complications.
Building on the foundation of general health education, Somerset Medical Center now provides detailed information on the specific risks associated with Fosamax (alendronate) therapy. Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the maxillofacial region, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section bridges the center's historical role in health education with the need for targeted risk communication regarding Fosamax and ONJ.
The clinical presentation of ONJ typically involves exposed bone in the jaw that persists for more than eight weeks, often accompanied by pain, swelling, infection, or drainage. Diagnosis is based on clinical examination and imaging, with exclusion of metastatic disease or other causes. The condition is staged from 0 (no clinical evidence but non-specific symptoms) to 3 (exposed bone with pathologic fracture or extraoral fistula). The multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/).
Fosamax pharmacology involves inhibition of osteoclast-mediated bone resorption, which reduces bone turnover. While this mechanism is beneficial for increasing bone mass and reducing fracture risk in osteoporosis, it can also impair the normal remodeling and repair processes in the jawbone. The mechanistic pathways linking Fosamax to ONJ are thought to involve suppression of bone turnover, leading to accumulation of microdamage, reduced blood supply, and increased susceptibility to infection and necrosis. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Safety communication regarding Fosamax and ONJ has been issued by regulatory agencies. The prescribing information for Fosamax includes a warning under section 5.4: "Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including FOSAMAX" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
Causation-focused clinical interpretation for affected patients requires careful assessment of the timeline between exposure and documented health outcomes. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a known adverse effect, its incidence in clinical trials was not significantly elevated compared to placebo, indicating that other factors may contribute to its development. For affected patients, eligibility for consideration of Fosamax as a cause of ONJ involves documenting exposure to the drug, ruling out other potential causes (e.g., cancer, radiation therapy, other medications), and establishing a temporal relationship. The introduction of equivalent dose (ED) and threshold dose (TD) metrics as predictive risk assessment tools may help in evaluating risk. In one study, ED for each medication was standardized to the cumulative dose of four years of weekly oral alendronate use (4 x 52 x 70 mg = 14,560 mg) (https://pubmed.ncbi.nlm.nih.gov/40619534/). This approach allows for comparison of risk across different bisphosphonates and dosing regimens.
In summary, the evidence supports a causal association between Fosamax and ONJ, particularly in patients with additional risk factors such as invasive dental procedures, cancer, or concomitant therapies. The risk appears to increase with longer duration of exposure. Clinical management should include dental evaluation before initiating bisphosphonate therapy, avoidance of invasive dental procedures during treatment if possible, and consideration of drug discontinuation for patients requiring such procedures. Patients who develop ONJ should discontinue Fosamax and receive appropriate dental care.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.
Fosamax (alendronate) is a bisphosphonate used to treat osteoporosis. Osteonecrosis of the jaw (ONJ) is a rare but serious condition involving exposed bone in the jaw that has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may increase with longer duration of use and in patients with additional risk factors such as dental procedures or cancer.
Risk factors include invasive dental procedures (e.g., tooth extraction, implants), cancer, chemotherapy, corticosteroids, poor oral hygiene, and pre-existing dental disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients should maintain good oral hygiene and undergo dental evaluation before starting Fosamax.
Diagnosis is based on clinical examination showing exposed bone in the jaw persisting for more than eight weeks, often with pain or infection. Imaging may be used to rule out other causes. Staging ranges from 0 (non-specific symptoms) to 3 (exposed bone with fracture or fistula) (https://pubmed.ncbi.nlm.nih.gov/40345077/).
If you develop jaw pain, swelling, or exposed bone, contact your healthcare provider immediately. You may need to discontinue Fosamax and receive appropriate dental care. Do not stop medication without consulting your doctor.
No. Submission requests an initial records screening only and does not create an medical context-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.